Drag a card by its title · ⚙ to size, swap or remove

The company

Exelixis, Inc.

EXEL · Nasdaq

Health CareBiotechnologyLeading

EXEL stood above a rising 150-day average in 46 of the last 52 weekly readings, including each of the last 30 weeks. It is 20.1% above that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

SEC filings

Statistics

Rotation: Leading
Weeks in an uptrend: 30 in a row
Industry in uptrend: 16% -15 in 4 wk
Insider buys, 12 months: $1.2M
Insider sales, 12 months: $74.0M
Officials’ trades on record: 4
Institutions holding: 707 (+54)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 46 of 52 weeks.

20 Apr – 19 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

4 disclosed lines: House 4, Senate 0, executive 0; 1 people.

Who	Did	Amount	Traded
Donna E. Shalala House: U.S. House ClerkFL27	sold	$1k–$15k	4 Jun 2019filed 27 Apr 2020
Donna E. Shalala House: U.S. House ClerkFL27	sold	$1k–$15k	16 Apr 2019filed 27 Apr 2020
Donna E. Shalala House: U.S. House ClerkFL27	bought	$1k–$15k	6 Feb 2019filed 27 Apr 2020
Donna E. Shalala House: U.S. House ClerkFL27	bought	$1k–$15k	9 Jan 2019filed 27 Apr 2020

Insiders

Buy orders, 12 months1

Sale orders, 12 months26

Buyers · sellers1 · 12

Who	Did	Shares	Traded
Mary C. BeckerleDirector	sold	9,812at $53.66	10 Aug 2026filed 12 Aug 2026
Sue Gail EckhardtDirector	sold	9,812at $50.14	1 Jun 2026filed 3 Jun 2026
Jack L. WyszomierskiDirector	sold	3,925at $50.55	1 Jun 2026filed 3 Jun 2026
Dana AftabEVP, Research and Development	sold	43,451at $50.35	26 May 2026filed 28 May 2026
Patrick J. HaleyEVP, Commercial	sold	32,110at $49.81	20 May 2026filed 22 May 2026
Brenda HeftiSVP and General Counsel	sold	6,625at $50.21	18 May 2026filed 19 May 2026
Christopher J. SennerEVP and CFO	sold	34,901at $50.00	18 May 2026filed 19 May 2026
George PosteDirector	sold	60,000at $45.71	7 May 2026filed 8 May 2026
Maria C. FreireDirector	sold	20,634at $46.00	7 May 2026filed 8 May 2026
Mary C. BeckerleDirector	sold	7,712at $48.45	7 May 2026filed 8 May 2026
Dana AftabEVP, Research and Development	sold	47,918at $44.50	24 Feb 2026filed 26 Feb 2026
Dana AftabEVP, Research and Development	sold	29,873at $44.35	19 Feb 2026filed 23 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders707+54 on the quarter

New · exited133 · 79

Reported value$13.4B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
BlackRock, Inc.reduced · filed 7 Aug 2026	29,075,377$1.6B	-1,740,932−5.6%
FARALLON CAPITAL MANAGEMENT, L.L.C.added · filed 14 Aug 2026	13,468,010$732.8M	+357,000+2.7%
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 2026	13,427,993$730.6M	-299,000−2.2%
VANGUARD PORTFOLIO MANAGEMENT LLCreduced · filed 13 Aug 2026	12,043,122$655.3M	-42,151−0.3%
AQR CAPITAL MANAGEMENT LLCreduced · filed 14 Aug 2026	11,023,943$598.6M	-2,071,798−15.8%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026	10,950,997$595.8M	-307,987−2.7%
STATE STREET CORPreduced · filed 7 Aug 2026	9,970,071$542.5M	-328,368−3.2%
FULLER & THALER ASSET MANAGEMENT, INC.added · filed 12 Aug 2026	8,929,389$485.8M	+387,153+4.5%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026	7,650,316$416.3M	-145,294−1.9%
D. E. Shaw & Co., Inc.added · filed 14 Aug 2026	5,551,747$302.1M	+1,948,684+54.1%